Nuzenio

Alterity Therapeutics Announces

Alterity Therapeutics Announces news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 4 latest news signals 3 publisher sources 100/100 entity strength

Latest news

Timeline

Thu, 06 Aug 2026 11:25:00 GMTAlterity CEO Set to Present at Canaccord Growth Conference - Stock Titan
Thu, 06 Aug 2026 10:06:42 GMTAlterity Therapeutics (NASDAQ: ATHE) plans Canaccord Growth Conference talk - Stock Titan
Thu, 30 Jul 2026 12:02:41 GMTAlterity Therapeutics clears FDA Phase 2 hurdle, plans Phase 3 trial for MSA drug ATH434 by end of 2026 - Pluang
Tue, 28 Jul 2026 07:00:00 GMTDasher Neuroscience Completes Patient Enrollment in Phase 2 Global Clinical Trial of Lead AI Drug Candidate YA-101 for Multiple System Atrophy (MSA) - Yahoo Finance

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Alterity Therapeutics Announces.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

3 distinct publisher/source names are currently connected to this entity page.